Okay. I think we're ready to get started. Good morning, everyone. Thanks, everyone, for joining us at the Guggenheim Healthcare Innovation Conference. Great to see everyone here in Boston. I'm Vamil Divan, one of the biopharma analysts here at Guggenheim, joined on the Guggenheim side with Daniel Krizay here on the stage. Our first session, we have Vicore Pharma joining us. Ahmed Mousa, the CEO, joining us up here on stage. Thanks so much, Ahmed, for joining us again. Maybe you can just, for those less familiar with the Vicore story, if you can maybe just give an overview on the background of the story and kind of where we're, big time coming up here in the next several months here, but just leading up to this kind of history would be helpful.
Yeah, absolutely. Thanks, Vamil and Dan and Guggenheim team for having Vicore back again this year. Vicore is a company that's really spent many years understanding and looking at how best to modulate the angiotensin II pathway. We've zeroed in on a receptor called the angiotensin II type 2 receptor that we actually believe can be a potent anti-fibrotic, vasodilatory, and anti-inflammatory intervention point. It's actually the body's own repair system. So actually, what we've created with our lead compounds is selective agonists of this repair system, this AT2 receptor system. We've gone after, as the initial disease, pulmonary fibrosis, and in particular idiopathic pulmonary fibrosis. So that's really the primary focus of the company right now. There are a lot of scientific reasons why we had a great deal of conviction that this was a very nice place to start with this mechanism of action.
In addition to that, of course, Vamil and Dan, as you know, the IPF field is a really tough one for patients. It's a disease that's quite fatal, only three to five year survival after diagnosis. Unfortunately, the standard of care therapies leave a lot to be desired in this space. So that was certainly one of the motivators as well for really making that the company's focus right now.
Okay, great. Your lead asset, buloxibutid, we'll get into the details on the ongoing trials. Maybe, again, just talk about the mechanism here. You touched on it there, but just why is AT2 receptor, why is that the right thing to target potentially for IPF?
Yeah. Let's then put this into the context of pulmonary fibrosis in the lung in particular. What happens in pulmonary fibrosis is you have initially injury to the lung, and in particular, it's injury to the epithelial cells that line the air sacs of the lung in the alveolar compartment. That injury causes decreased gas exchange capability. It causes the alveoli to collapse on themselves. It's called pre-fibrotic alveolar collapse. Then it also causes a buildup of fibrosis, and that's because these epithelial cells, when they become injured, they start producing TGF-β, other injury signals, and that causes around these air sacs to start to build that scarring or that fibrotic matrix. That functions as a physical barrier to oxygen diffusion, because what's supposed to happen is oxygen should be crossing across that epithelial layer of the alveolus and ultimately into the pulmonary vasculature.
As you have that fibrosis buildup, it becomes more and more challenging to oxygenate your blood. In addition to that, of course, that fibrotic material as it builds up can be physically constricting to the lung, which is a huge challenge. In addition to that, the fibrotic material as it builds up also starts to injure the pulmonary vasculature, which is actually why many patients with pulmonary fibrosis, including IPF, eventually develop pulmonary hypertension as well, which is kind of when the pulmonary vasculature becomes narrowed and injured, and then that also has its own challenges. Many companies that are working on pulmonary fibrosis therapies look at what happens after that injury signal, that fibrosis signal, and look to block something in that cascade, which is not an invalid way to go after the disease, but we think it's only partial.
What we're doing at Vicore with buloxibutid is by activating this angiotensin II type 2 receptor, this receptor's actually highly expressed on stem cells in the epithelium, in alveolar epithelial type 2 cells. We drive essentially a reproliferation and a refunctionalization of one of the very cell types that becomes injured and essentially kicks off this disease. We believe that's a very nice way to go after this disease because you can then replenish that gas exchange capability. You can address that pre-fibrotic alveolar collapse, so kind of the stuff that happens in pulmonary fibrosis even before that fibrotic buildup. In addition to that, these actually epithelial cells, type 2 epithelial cells, are one of the main mediators of the fibrosis because they release TGF-β and other profibrotic cytokines.
When they're brought back into their more normal state, that elevated level of TGF-β is attenuated. Then you can naturally then address, using this intervention point, you can address the kind of new fibrotic buildup. In addition to that, this mechanism is known to resolve fibrosis, and it does it by upregulating matrix metalloproteinases that are collagenases, so essentially enzymes that will digest existing fibrotic matrix. True to that form, we've seen some nice data, both pre-clinically and clinically, that we can essentially help resolve fibrosis, which is also a really nice part of this mechanism of action. Finally, of course, if we know anything about the angiotensin II pathway, it's vasoactive, and this mechanism's also vasodilatory and does have a role in addressing that vascular remodeling component.
As patients develop that pulmonary hypertension or vascular dysfunction phenotype, we believe this can also be a nice intervention point there. We are really excited about this mechanism, across having an impact on the epithelium, in the interstitium, on the buildup of fibrosis, and then also on the vascular dysfunction side. We think we can play a pretty big role in going after IPF. The other thing I would say also is that many of the approaches currently that are pursued in IPF, because they are trying to go after blocking profibrosis drive, it tends to be very difficult to distinguish between pathological profibrotic drive and normal extracellular matrix maintenance or homeostasis. Actually, there are a number of therapies in the field that have failed due to toxicity issues or that have significant tolerability issues as a result of that.
We think by going a little bit orthogonal to that, we also have not seen those types of challenges in our kind of safety and tolerability profile to date.
Okay, great. We have the phase IIb trial ongoing. Couple questions here. One, you just passed a futility analysis in the trial. Maybe you can just clarify for everyone exactly what that means, what it does not mean, and then kind of we are setting the stage for what we will see next year, the top line data. Still think mid-next year, maybe just kind of set the stage for what to expect there.
Yeah, absolutely. For those less familiar with the story, right, we have taken then that mechanistic concept, a lot of really nice preclinical and translational data showing that it does what we believe it should be doing, and then we saw a really nice signal in an open-label nine-month study. We show stabilization, maybe even improvement in lung function. That is observed dataset, open label, so it is a nice signal, but we need to really confirm it with what we are doing now, which is a large phase IIb trial, almost 400 patients, 52-week endpoint, same endpoint as in many of the phase III trials in IPF, actually all of the phase III trials in IPF. What we recently completed was a futility analysis, and that futility analysis was designed basically to ensure that we had a greater than at least 20% conditional power to see the end result.
It's a relatively conservative setup, but actually it was designed to really mitigate the risk that many IPF therapies in development have unfortunately succumbed to, which is that they have significant tolerability or toxicity issues that are observed only in these larger 52-week trials, or actually that they're even having a detrimental impact on lung function. Unfortunately, we've seen in the field many cases like that. We're very pleased to have cleared that ultimate milestone and really looking forward to the top line data in the middle of next year.
Okay. On that top line, maybe it will be helpful, I think, just to frame what you're hoping to see. What would be a successful outcome in that trial?
Yeah. The bar in IPF, unfortunately, is very low, right? That's because, as we mentioned, fatal disease, current standard of care therapies are tough to tolerate. 25%, unfortunately, it's a couple years ago, but studies have shown only 25% of patients in the U.S., for example, even initiate IPF therapy despite how fatal the disease is. Then, unfortunately, discontinuation also is relatively rapid, within less than a year. That's because these drugs are not really significantly moving the needle on lifespan, unfortunately, and also they have all these liabilities, in particular gastrointestinal side effects, nausea, diarrhea. Really, what there's a huge interest in is well-tolerated therapies. If you have a well-tolerated therapy, I think that really any level of efficacy would be quite welcome, particularly since what clinicians really want to do here is combine these therapies with each other.
For example, nerandomilast, a recently approved drug for IPF, we understand from clinicians and others that it's launching very, very well. Even though efficacy-wise it's probably similar to the approved therapies, it's because it's actually a little bit gentler in terms of those GI side effects, although it does still have them. Where that positions buloxibutid is actually quite nice because we've already done nine months clinical development in the phase IIa. We saw a good safety and tolerability profile. We haven't seen anything in the blinded dataset. Our data monitoring committee has cleared us without suggesting any changes to the trial.
I think what that means from an efficacy perspective is starting at the level of efficacy that nerandomilast showed JASCAYD, which is about 65-70 mils difference in lung function from the placebo arm to the treatment arm, and then going up from there. But certainly, if you can have something well-tolerated that clinicians can use actually not just by itself, but in combination with others, I think that would make them very excited. Because even though nerandomilast, we understand, is getting very good uptake, the one challenge with that one is because it has the same type of side effect as the other approved therapies, it's very challenging for clinicians to do kind of like doublet therapy with that new medication.
Okay. Then maybe last question for me, then I'll turn over to Daniel. Just around, so again, leading into the top line data mid-next year, assuming it's successful, maybe you could lay out the path looking forward beyond the phase IIb into the registrational side of things.
Yeah, absolutely. So the path is relatively well-established in IPF. The pulmonary division FDA has made clear what they're looking for. We believe we can move to approval with a single phase III, which would actually have materially similar design and inclusion criteria as our ongoing phase IIb. Our ongoing phase IIb is 14 countries, over 100 clinical sites. The phase III studies range from 600 to 1,200 patients that have been conducted, depending on the effect size that's being sought and the overall design and setup. That's what we'd look forward to do. In our phase IIb trial, we're allowing patients on background therapy and those who are not on background therapy, whether that's because they've chosen not to take it, which is actually pretty significant.
Two-thirds of the patients in our phase IIb are not on background therapy and have never taken any background therapy in the past, for those who are not on background. Then, in addition to that, allowing patients who are on nintedanib or pirfenidone, the newly approved therapy standard of care. We would certainly do something similar in the phase IIb, where we'd look for kind of broad allowance of patients who are on background therapies or who've chosen or are unfortunately unable to tolerate the existing standard of care therapies as well.
Okay. Great. Let me turn over to Daniel.
Yeah, great. Obviously, as you mentioned, the IPF landscape has evolved dramatically in the last couple of years. You mentioned JASCAYD's launching. We have had some positive clinical data from some competitors, Tyvaso, recently with BMS. I guess, what are your key takeaways from how this field is evolving? How do they sort of shape your view on where buloxibutid can fit into this?
Yeah, absolutely. I think what is clear from our perspective is that the clinical and regulatory community are looking for combination paradigms, just as in pulmonary hypertension space. I think that, for example, positions buloxibutid very well because of our good safety and tolerability profile. When you think about the landscape as it is emerging, that has been one of the challenges of nintedanib, although candidly, clinicians are very happy to have a new therapy that is better tolerated than what is existing. We do see evidence that that is very popular, and I would imagine as we move. We had a handful of patients in our phase IIb who enrolled on JASCAYD background. We were finishing up our enrollment just as they were starting up their launch.
We would imagine in the phase III setting, we would probably have a greater proportion of patients on JASCAYD background therapy. It will be very interesting to see the admilparant data, which is BMS's program for IPF, because they have signaled in their press release that that is a well-tolerated therapy. If that is indeed true, I think that could be a very popular one, even though from what we can tell, it is likely to be an incremental efficacy therapy, right? Because their high dose unfortunately did not reach statistical significance, so they have an effect in their lower dose. I would say even a modest effect, well-tolerated therapy, likely would be very well received, and then you could think about subsequent molecules such as buloxibutid being nice combination partners to that.
I certainly think that for some of the kind of legacy standard of care therapies that are tough to tolerate, I think there is an interest in even allowing them to sunset. As new kind of therapies come forward, perhaps some of those other ones are less frequently used. Tyvaso certainly showed a nice effect size, although they used slightly different statistical methods to analyze the effect size, so it's hard to make the direct comparison to nintedanib dataset, JASCAYD dataset so far. I think the challenge with that therapy right now is that it's a four times a day nebulized with significant coughing and other side effects. Again, this is probably currently in the zone of a tougher to tolerate therapy, but let's see how it's received. Their PDUFA date is in April, I believe, and I would anticipate that it's approved.
There are also follow-on formulations of the drug that I believe both United Therapeutics and others are developing that might be less likely to drive significant cough side effect and can be taken less frequently each day, and that certainly might be attractive over time to patients as well.
Okay, great. You mentioned the admilparant dose response, I guess, where the higher dose didn't work. You tested two doses yourself in ASPIRE. What are you hoping to see across these two doses, and do you think a dose response is something that is necessary for your drug, or how are you kind of viewing that?
Yeah, I mean, I would anticipate that if BMS's therapy is efficacious at the lower dose and well-tolerated at the lower dose, that they could get approval for the therapy. I don't think that dose response is necessary in this context, in this field. I would certainly say the same for us. Based on all the data that we have, I would imagine that we do observe some dose response effect, whether that's statistically significant or not, like the 50 versus 100 are significantly different from each other. I think that'll be interesting to see. This is a space where there's variability in FVC. That's why these endpoints are long. They're one year out, and that's why also we enroll relatively large trials.
But again, with a disease like this and the bar being so low, I do think that when you show efficacy at either dose, you will be able to move forward. Certainly, how we think about then those two doses moving forward as we go to phase III and launch, I think it really depends on the efficacy and then the comparative tolerability. We do have, like in the phase IIa, we did observe some hair loss or hair thinning described as mild to moderate in 20% of the patients who enrolled in our phase IIa. Certainly that is something we are looking to see, can we further mitigate that with a lower dose while also not sacrificing on efficacy? We have some reason to believe the 50 milligram dose will also be efficacious, and that was one of the reasons why we advanced it into the phase IIb.
But in the phase IIa, we only tested that 100 milligram dose, so we will still have to see how that looks. Certainly if both doses look good and offer some kind of differential benefit to patients, there is also an option to advance both into phase III. This is done as well so that you can give the choice to patients and clinicians, which one makes the most sense for them.
Okay. You are looking at buloxibutid in IPF, but what is the potential of this mechanism in other indications, whether it is in respiratory medicine or also maybe even beyond?
Yeah. So maybe just stepping back, this AT2 receptor that we are activating is this, as I mentioned, endogenous tissue repair fibrosis resolution system, has anti-inflammatory and vasodilatory effects. It is actually the opposing force of a very familiar system called the AT1 receptor. The AT1 receptor does the opposite. So it is profibrotic, pro-inflammatory, and hypertensive. It is the receptor that is blocked by ACE inhibitors and ARBs. So losartan and the sartan class are AT1 receptor antagonists. Just like blocking the AT1 can be very safe and well-tolerated, as we have seen, of course, many Americans take these types of therapies for different diseases, we believe activating the AT2 can also be very fruitful in a number of indications.
Certainly in the lung space, we think about other types of pulmonary fibrosis, like progressive pulmonary fibrosis, which is essentially a basket of other interstitial lung diseases with decline in lung function. We also think about pulmonary hypertension as a space we could potentially go. As I mentioned, this mechanism is vasoactive, and certainly there is precedent for thinking about both indications depending on your mechanism. United Therapeutics initially approved in pulmonary hypertension and now showed some nice data in pulmonary fibrosis as well. Then certainly, this is not a mechanism that is limited to the lung. So we think about fibrotic and other associated diseases in other organs, and certainly we have started generating a lot of data and thinking a lot about what organs we could go into and what disease states in particular we go into.
We look forward to talking a little bit more about that in the future. That could, for example, not necessarily be fixed on buloxibutid, but rather even some of the follow-on molecules that we are working on as well.
Okay. In the last few minutes here, maybe we just bring you back to the corporate side here. Maybe you can talk about what your cash runway is.
Yeah
right now, and kind of the events that are leading up through that cash.
Yeah. We are very happy to have sufficient capital to finish this large phase IIb readout that I mentioned, and actually have a year of cash thereafter. For the readout in mid-2027 and thereafter. I think that puts us in a really nice position to kind of see what this impactful dataset will look like in IPF, and I think that should provide us with kind of clear options on how we want to develop the company moving forward in terms of supporting phase III, as well as some of these other indications that you asked about, Daniel, and follow-on pipeline as well.
You mentioned this, obviously, data dependent. You do have one partnership in Japan already. How are you thinking about this from a more global perspective, this asset?
Yeah. We thought Japanese partnership a little bit early would make a lot of sense. They tend to have slightly different regulatory requirements, and we really enjoyed the discussion with Nippon Shinyaku, who actually have developed and commercialized some of the drugs in pulmonary hypertension in Japan, including Uptravi, who they then out-licensed the ex-Japanese rights for. So they have a great experience there. They have been a great partner in helping us think about how we then run a global phase III that would include a significant Japanese component. I think for other geographies, we would probably wait until we see the phase IIb dataset and think a little bit about how then we want to kind of build the program in terms of executing a phase III, as well as, of course, commercial launch considerations.
Okay. Last question. You did recently just do a U.S. listing for the company. Maybe you can talk about the strategy there and how you think about building out your presence in the U.S. further.
Absolutely. Vicore has been European listed for some time, since 2018, and then now over the summer, U.S. listed as well. I think that's a natural byproduct of the financings that we conducted to support the phase IIb development, brought in a lot of U.S. institutional investors, which I think is a natural part of a company's progression as kind of the capital need and the development stage moves forward. Certainly, we would look forward to leveraging that U.S. listing more over time as well, in terms of getting better access to the U.S. capital markets and better exposure with U.S. institutional investors. Certainly, I think already it's played that role in sort of capturing attention, folks who might not otherwise look at European-traded companies as well.
Okay. Great. I think why don't we leave it there. Thanks so much again for joining us. Good luck in the coming months. Big year coming up for Vicore.
Thank you, Vamil. Thank you, Daniel.
Thank you.